Anant Murthy is the Chief Operating Officer at Hemab Therapeutics, bringing over 25 years of expertise in the healthcare sector, including executive leadership roles in market access, commercialization, and strategy. Prior to Hemab, he served as General Manager of EMEA for argenx, where he built and led the company’s presence across a broad international region. While there, Anant delivered one of the most successful biopharmaceutical product launches in Europe and created a sustainable launch platform for an expanding pipeline. Previously, he was a Vice President at Alnylam Pharmaceuticals, where he led pricing and market access and served as General Manager for multiple international markets. He oversaw the launch of Alnylam’s RNAi portfolio across multiple countries and secured approvals from payers and governments across Europe and Canada. Anant’s career also includes senior leadership roles at Incyte Corporation, Ariad Pharmaceuticals, and Celgene Corporation.  Earlier in his career, he held roles at Medtronic, Ernst & Young LLP, and served as an aide to a member of the U.S. House of Representatives. Anant is also a Co-Founder and Board Member of Avanzanite Bioscience, a rapidly growing commercial-stage company. He holds a PhD from the Johns Hopkins Bloomberg School of Public Health, an MSc from the London School of Economics, and a BA from the University of Rochester.